藥明康德(02359.HK)料中期純利按年升73% 將全年收入增長目標上調至68至72%
藥明康德(02359.HK)公布,目前,經公司財務部門測算,今年上半年公司取得創紀錄的收入增長,實現營業收入約177.56億元人民幣(下同),按年增長68.52%;歸屬於公司股東的淨利潤46.36億元,按年增長73.29%;經調整非《國際財務報告準則》下歸屬於公司股東的淨利潤43.01億元,按年增長75.68%。
公司指出,有信心將2022年全年收入增長目標由此前公告的65%至70%,上調至68%至72%,顯示公司在合同研究、開發與生產(CRDMO)和合同測試、研發與生產(CTDMO)業務模式驅動下持續加速發展的信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.